跳至主要内容
临床试验/ACTRN12617000994381
ACTRN12617000994381招募中1 期

Evaluating ease of use and acceptability of a perineal measuring device (Episiometer) in ensuring correct angle and length of mediolateral episiotomy: a mixed methods study

Professor Ajay Rane0 个研究点目标入组 120 人开始时间: 2017年7月10日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
Professor Ajay Rane

相似试验

进行中(未招募)
Unknown
Evaluating the acceptability and usability of a digital self-management intervention (smartphone application) to support the non-surgical treatment of Perthes' DiseasePerthes' DiseaseMusculoskeletal Diseases
ISRCTN14517832niversity of Leeds30
进行中(未招募)
Unknown
Precision Atrial Fibrillation App to support Atrial Fibrillation ManagementCardiovascular - Other cardiovascular diseasesAtrial Fibrillation
ACTRN12623001051639The University of Adelaide30
招募中
不适用
Pilot trial of the Health4Life apppoor dietinsufficient physical activityalcohol usetobacco usepoor sleepexcessive recreational screen timePublic Health - Health promotion/education
ACTRN12622001087741HMRC CTC75
已完成
不适用
The usability and preliminary effectiveness of an app-based training and educational program (Join2Move) in people with hip and/ or knee osteoarthritis – a randomized controlled pilot studyPolyarthrosisPeople with hip and/ or knee OA diagnosed by a physician or self-reported OA. Self-reported OA should meet the criteria of idiopathic OA of the hip (Altman et al., 1991) or OA of the knee (Altman et al., 1986).M15M16M17Coxarthrosis [arthrosis of hip]Gonarthrosis [arthrosis of knee]
DRKS00027164Hochschule für Gesundheit Bochum61
进行中(未招募)
1 期
To assess ease of use, acceptability and preference of Norditropin NordiFlex® in subjects on prescribed growth hormone therapychildren aged 6 years or more receiving growth hormone therapy for the following approved indications (according to Norditropine SPC)-GHD-Turner Syndrome-small for gestational age-chronic renal insufficiency
EUCTR2009-017387-16-FRovo Nordisk Pharmaceutique S.A.S